4:53 PM
 | 
Aug 23, 2017
 |  BC Extra  |  Preclinical News

Genentech reports preclinical data for p300/CBP inhibitor in prostate cancer

Preclinical evidence supporting dual inhibition of E1A binding protein p300 (EP300; p300) and CREB binding protein (CREBBP; CBP) as an epigenetic strategy for treating prostate cancer is mounting.

In a paper published in Cancer Research, researchers at the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) reported development of a small molecule p300/CBP bromodomain inhibitor, GNE-049, that blocked expression of key proliferative...

Read the full 311 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >